No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 11
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:25:49.881Z. Latest historical point 2025-05-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Artiva Biotherapeutics, Inc. (ARTV) stock was $7.27 as of Oct 6, 2026, 4:00 PM EDT, up 1.96% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +140.7%
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer.
Biotechnology · San Diego, CA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.54
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.63
vs Estimate
$-0.64
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ARTV | $355.43M | $7.27 | +1.96% | +140.68% | N/A | N/A | N/A |
| 2VMD | $355.36M | $9.33 | +0.97% | +33.15% | +10.93% | N/A | vs ARTV |
| 3ENTA | $353.88M | $12.17 | -3.41% | +21.86% | -26.94% | -7.11% | vs ARTV |
| 4EMBC | $353.00M | $5.95 | +1.19% | -57.42% | N/A | N/A | vs ARTV |
| 5OCGN | $352.67M | $1.04 | +0.00% | -41.09% | -31.57% | -40.73% | vs ARTV |
| 6FENC | $359.53M | $10.35 | -2.54% | +7.45% | +2.45% | N/A | vs ARTV |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 5 analysts
Average Price Target
$35.80
+392.4% upside
Low
$23.00
Current
$7.27
High
$41.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.57 | $-0.55 | $-0.54 | 4 |
| Quarter ending Dec 2026 | $-0.62 | $-0.59 | $-0.57 | 4 |
| Quarter ending Mar 2027 | $-0.64 | $-0.64 | $-0.64 | 1 |
| Quarter ending Jun 2027 | $-0.62 | $-0.62 | $-0.62 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.72 | $-2.59 | $-2.49 | 5 |
| FY 2027 | $-3.21 | $-2.70 | $-2.18 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
